{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-088956","form_type":"8-K","ticker":"ALMS","cik":"0001847367","company_name":"ALUMIS INC.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.885134+00:00","generated_at":"2026-05-31T09:49:37.563145+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Alumis Q2 net loss $56.5M, cash $209.5M; Phase 3 psoriasis trial initiated","bullets":["Net loss $56.5M for Q2 2024 vs $36.3M in Q2 2023; R&D expense $48.6M (up from $32.8M).","Cash and marketable securities $209.5M at June 30; IPO net proceeds $233.2M extend runway into 2026.","Initiated ESK-001 Phase 3 ONWARD program in moderate-to-severe plaque psoriasis; topline expected 2026.","Completed IPO and concurrent private placement raising $250M gross proceeds (15.625M shares at $16.00).","Phase 1 trial for A-005 (CNS-penetrant TYK2 inhibitor) dosed first healthy volunteer in April 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-088956","json":"https://secwatch.observer/filing/0001104659-24-088956.json","markdown":"https://secwatch.observer/filing/0001104659-24-088956.md","text":"https://secwatch.observer/filing/0001104659-24-088956.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847367/000110465924088956/0001104659-24-088956-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847367/000110465924088956/tm2421483d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:49:37.563145+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}